EU Court Adviser Sides With Merck In Patent Term Fight

Law360, New York (June 9, 2011, 5:13 PM EDT) -- Drugmakers should still get patent protection extensions designed to make up for time spent testing drugs for pediatric use even if their products win marketing approval within five years, an adviser to the European Union's highest court said Thursday.

The EU's pharmaceutical regulatory framework is designed to guarantee patent holders up to 15 years of exclusivity from the time they receive marketing approval with another six months of protection to make up for time spent testing whether a drug is safe enough for children to use,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.